cardiovascular-agents and edoxaban

cardiovascular-agents has been researched along with edoxaban* in 2 studies

Trials

1 trial(s) available for cardiovascular-agents and edoxaban

ArticleYear
Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2013, Volume: 13, Issue:5

    Edoxaban, an oral direct factor Xa inhibitor, is in development for thromboprophylaxis, including prevention of stroke and systemic embolism in patients with atrial fibrillation (AF). P-glycoprotein (P-gp), an efflux transporter, modulates absorption and excretion of xenobiotics. Edoxaban is a P-gp substrate, and several cardiovascular (CV) drugs have the potential to inhibit P-gp and increase drug exposure.. To assess the potential pharmacokinetic interactions of edoxaban and 6 cardiovascular drugs used in the management of AF and known P-gp substrates/inhibitors.. Drug-drug interaction studies with edoxaban and CV drugs with known P-gp substrate/inhibitor potential were conducted in healthy subjects. In 4 crossover, 2-period, 2-treatment studies, subjects received edoxaban 60 mg alone and coadministered with quinidine 300 mg (n = 42), verapamil 240 mg (n = 34), atorvastatin 80 mg (n = 32), or dronedarone 400 mg (n = 34). Additionally, edoxaban 60 mg alone and coadministered with amiodarone 400 mg (n = 30) or digoxin 0.25 mg (n = 48) was evaluated in a single-sequence study and 2-cohort study, respectively.. Edoxaban exposure measured as area under the curve increased for concomitant administration of edoxaban with quinidine (76.7 %), verapamil (52.7 %), amiodarone (39.8 %), and dronedarone (84.5 %), and exposure measured as 24-h concentrations for quinidine (11.8 %), verapamil (29.1 %), and dronedarone (157.6 %) also increased. Administration of edoxaban with amiodarone decreased the 24-h concentration for edoxaban by 25.7 %. Concomitant administration with digoxin or atorvastatin had minimal effects on edoxaban exposure.. Coadministration of the P-gp inhibitors quinidine, verapamil, and dronedarone increased edoxaban exposure. Modest/minimal effects were observed for amiodarone, atorvastatin, and digoxin.

    Topics: Adolescent; Adult; Anticoagulants; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cardiovascular Agents; Cohort Studies; Cross-Over Studies; Drug Interactions; Factor Xa Inhibitors; Female; Humans; Male; Pyridines; Thiazoles; Young Adult

2013

Other Studies

1 other study(ies) available for cardiovascular-agents and edoxaban

ArticleYear
Cardiovascular drugs.
    Nursing, 2017, Volume: 47, Issue:11

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzazepines; Cardiovascular Agents; Humans; Ivabradine; Pyridines; Thiazoles

2017